The Rac1 Promoter as a Molecular Nexus for Antihypertensive Therapy Resistance and Enhanced Malaria Susceptibility

Background In Sub‐Saharan Africa, the escalating burden of hypertension converges with persistent malaria endemicity, creating a complex clinical challenge marked by increasing rates of resistance to first‐line antihypertensive therapies, particularly angiotensin‐converting enzyme inhibitors (ACEIs) and Angiotensin II receptor blockers (ARBs). The molecular mechanisms underpinning this therapeutic failure remain elusive. Rac1 , a Rho GTPase regulating both cardiovascular function and erythrocyte biology, presents a compelling molecular link between these comorbidities, yet its regulatory architecture in this context is uncharacterized. Methods We conducted a comprehensive in silico analysis of the human Rac1 promoter region (−2000 to +500 bp relative to the transcription start site) using biomaRt, BSgenome, and the JASPAR2022 database, anchored to the GRCh38/hg38 reference genome. African ancestry variants from resources such as gnomAD were considered to enhance population‐specific relevance. Transcription factor binding sites were predicted using position weight matrices with an 80% relative score threshold to balance sensitivity and specificity. CpG island analysis was performed, including calculation of the observed/expected (o/e) ratio. Results The 2501 bp Rac1 promoter is notably GC‐rich (57.34%) and contains 164 CpG sites with an o/e ratio of 0.75, defining a canonical CpG island. Analysis revealed a complex regulatory landscape featuring binding motifs for the mineralocorticoid receptor (MR), suggesting a potential pathway for bypassing RAAS blockade and contributing to ACEI/ARB resistance. Binding sites for hypoxia‐inducible factors, inflammatory mediators, and the erythroid‐specific factor GATA‐1 were also identified. Spatial analysis showed nonrandom clustering of these elements, suggesting integrated response capabilities. Conclusion The regulatory architecture of the Rac1 promoter suggests a potential molecular basis for MR‐mediated resistance to ACEI/ARB therapies while simultaneously providing a predictive link to enhanced malaria susceptibility through erythrocyte remodeling pathways. These findings offer a novel framework for understanding treatment‐resistant hypertension in malaria‐endemic regions and identify the Rac1 promoter as a candidate nexus for developing dual‐disease therapeutic strategies tailored to high‐burden populations.